David Adlington
JPMorgan Chase & Co, Research Division
Good afternoon, everybody. I’m David Adlington. I head up the JPMorgan research team for MedTech in London for JPMorgan. It’s my pleasure to introduce Dr. Montag and Jochen, CFO as well from Healthineers. There will be a presentation in a moment. Thank you.
Bernhard Montag
President, CEO & Chairman of Management Board
So thank you, David. So as a preview, I mean, this is going to be a very important year for Siemens Healthineers here because many of you know that more shares will be available soon, yes.
So that is why I will start a little bit in the beginning about really who we are so that this is really clear. And on the other hand, this is why we team up today, and Jochen will also present, which means I need to speak very fast so that he has also some time and doesn’t criticize me too hard afterwards.
So with that said, who are we? We are a clear market leader and compounder. We are a clear #1 in imaging and in precision therapy. We are seen as the go-to partner for the big institutions for the academic medical centers, 90% of them work with us.
We are global, global in the sense of being present in 70 countries. We have an installed base of about 700,000 systems and an impressive number, 3 billion patient touch points per year.
R&D is for us not a cost, but the lifeblood of
